{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:23:03Z","timestamp":1791501783464,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T00:00:00Z","timestamp":1338768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T00:00:00Z","timestamp":1338768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2013,4,18]]},"DOI":"10.1038\/onc.2012.219","type":"journal-article","created":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T16:17:27Z","timestamp":1338826647000},"page":"2096-2106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["TGF-\u03b2-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1\/CD20"],"prefix":"10.1038","volume":"32","author":[{"given":"K C","family":"Kawabata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Miyazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,4]]},"reference":[{"key":"BFonc2012219_CR1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1440-1827.2000.01108.x","volume":"50","author":"Lymphoma Study Group of Japanese Pathologists","year":"2000","unstructured":"Lymphoma Study Group of Japanese Pathologists. The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696\u2013702.","journal-title":"Pathol Int"},{"issue":"1","key":"BFonc2012219_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/asheducation-2009.1.523","volume":"2009","author":"E. S. Jaffe","year":"2009","unstructured":"Jaffe E . The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology (Am Soc Hematol Educ Program) 2009; 523\u2013531.","journal-title":"Hematology"},{"key":"BFonc2012219_CR3","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood.V77.7.1516.1516","volume":"77","author":"B Shiramizu","year":"1991","unstructured":"Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla-Favera R, Neri A et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991; 77: 1516\u20131526.","journal-title":"Blood"},{"key":"BFonc2012219_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1182\/blood-2005-01-0168","volume":"106","author":"C Bellan","year":"2005","unstructured":"Bellan C, Lazzi S, Hummel M, Palummo N, de Santi M, Amato T et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106: 1031\u20131036.","journal-title":"Blood"},{"key":"BFonc2012219_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533\u2013538.","journal-title":"Nature"},{"key":"BFonc2012219_CR6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/gcc.20345","volume":"45","author":"JE Guikema","year":"2006","unstructured":"Guikema JE, de Boer C, Haralambieva E, Smit LA, van Noesel CJ, Schuuring E et al. IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination. Genes Chromosomes Cancer 2006; 45: 808\u2013819.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2012219_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jb\/mvp148","volume":"147","author":"K Miyazono","year":"2010","unstructured":"Miyazono K, Kamiya Y, Morikawa M . Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35\u201351.","journal-title":"J Biochem"},{"key":"BFonc2012219_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature02006","volume":"425","author":"R Derynck","year":"2003","unstructured":"Derynck R, Zhang YE . Smad-dependent and Smad-independent pathways in TGF-\u03b2 family signalling. Nature 2003; 425: 577\u2013584.","journal-title":"Nature"},{"key":"BFonc2012219_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9 J . TGF-\u03b2 in cancer. Cell 2008; 134: 215\u2013230.","journal-title":"Cell"},{"key":"BFonc2012219_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrc1926","volume":"6","author":"B Bierie","year":"2006","unstructured":"Bierie B, Moses HL . Tumour microenvironment: TGF\u03b2: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506\u2013520.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2012219_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00441-011-1179-5","volume":"347","author":"H Ikushima","year":"2012","unstructured":"Ikushima H, Miyazono K . TGF-\u03b2 signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-\u03b2. Cell Tissue Res 2012; 347: 37\u201349.","journal-title":"Cell Tissue Res"},{"key":"BFonc2012219_CR12","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1038\/sj.onc.1208923","volume":"24","author":"HK Lin","year":"2005","unstructured":"Lin HK, Bergmann S, Pandolfi PP . Deregulated TGF-\u03b2 signaling in leukemogenesis. Oncogene 2005; 24: 5693\u20135700.","journal-title":"Oncogene"},{"key":"BFonc2012219_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031197","volume":"351","author":"LA Wolfraim","year":"2004","unstructured":"Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004; 351: 552\u2013559.","journal-title":"N Engl J Med"},{"key":"BFonc2012219_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nature02783","volume":"431","author":"HK Lin","year":"2004","unstructured":"Lin HK, Bergmann S, Pandolfi PP . Cytoplasmic PML function in TGF-\u03b2 signalling. Nature 2004; 431: 205\u2013211.","journal-title":"Nature"},{"key":"BFonc2012219_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1006\/excr.1998.4096","volume":"242","author":"A Saltzman","year":"1998","unstructured":"Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y . Transforming growth factor-\u03b2-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res 1998; 242: 244\u2013254.","journal-title":"Exp Cell Res"},{"key":"BFonc2012219_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1074\/jbc.M808080200","volume":"284","author":"LC Spender","year":"2009","unstructured":"Spender LC, Inman GJ . TGF-\u03b2 induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1. J Biol Chem 2009; 284: 1435\u20131442.","journal-title":"J Biol Chem"},{"key":"BFonc2012219_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng1001-117","volume":"29","author":"R Derynck","year":"2001","unstructured":"Derynck R, Akhurst RJ, Balmain A . TGF-\u03b2 signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117\u2013129.","journal-title":"Nat Genet"},{"key":"BFonc2012219_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1006\/excr.1998.4096","volume":"242","author":"A Saltzman","year":"1998","unstructured":"Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y . Transforming growth factor-\u03b2-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res 1998; 242: 244\u2013254.","journal-title":"Exp Cell Res"},{"key":"BFonc2012219_CR19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM . Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424\u20131433.","journal-title":"Blood"},{"key":"BFonc2012219_CR20","doi-asserted-by":"publisher","first-page":"15150","DOI":"10.1021\/bi0511078","volume":"44","author":"JA Ernst","year":"2005","unstructured":"Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL . Isolation and characterization of the B-cell marker CD20. Biochemistry 2005; 44: 15150\u201315158.","journal-title":"Biochemistry"},{"key":"BFonc2012219_CR21","first-page":"251","volume":"67","author":"T van Meerten","year":"2009","unstructured":"van Meerten T, Hagenbeek A . CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med 2009; 67: 251\u2013259.","journal-title":"Neth J Med"},{"key":"BFonc2012219_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1349-7006.2009.01392.x","volume":"101","author":"S Uchiyama","year":"2010","unstructured":"Uchiyama S, Suzuki Y, Otake K, Yokoyama M, Ohta M, Aikawa S et al. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci 2010; 101: 201\u2013209.","journal-title":"Cancer Sci"},{"key":"BFonc2012219_CR23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 1103\u20131108.","journal-title":"J Clin Oncol"},{"key":"BFonc2012219_CR24","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1182\/blood.V99.9.3256","volume":"99","author":"MJ Polyak","year":"2002","unstructured":"Polyak MJ, Deans JP . Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99: 3256\u20135362.","journal-title":"Blood"},{"key":"BFonc2012219_CR25","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-09-1234","volume":"15","author":"MI Vega","year":"2009","unstructured":"Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, Gonz\u00e1lez-Bonilla CR et al. Rituximab-mediated cell signaling and chemo\/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009; 15: 6582\u20136594.","journal-title":"Clin Cancer Res"},{"key":"BFonc2012219_CR26","first-page":"5545","volume":"55","author":"LL Myeroff","year":"1995","unstructured":"Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K et al. A transforming growth factor \u03b2 receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995; 55: 5545\u20135547.","journal-title":"Cancer Res"},{"key":"BFonc2012219_CR27","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","volume":"15","author":"A Blackford","year":"2009","unstructured":"Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15: 4674\u20134679.","journal-title":"Clin Cancer Res"},{"key":"BFonc2012219_CR28","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1182\/blood.V97.9.2815","volume":"97","author":"K Izutsu","year":"2001","unstructured":"Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H . The corepressor CtBP interacts with Evi-1 to repress transforming growth factor \u03b2 signaling. Blood 2001; 97: 2815\u20132822.","journal-title":"Blood"},{"key":"BFonc2012219_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1349-7006.2009.01152.x","volume":"100","author":"S Goyama","year":"2009","unstructured":"Goyama S, Kurokawa M . Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 2009; 100: 990\u2013995.","journal-title":"Cancer Sci"},{"key":"BFonc2012219_CR30","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1099\/0022-1317-81-6-1567","volume":"81","author":"GJ Inman","year":"2000","unstructured":"Inman GJ, Allday MJ . Resistance to TGF-\u03b21 correlates with a reduction of TGF-\u03b2 type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 2000; 81: 1567\u20131578.","journal-title":"J Gen Virol"},{"key":"BFonc2012219_CR31","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1182\/blood-2005-06-2341","volume":"106","author":"C Mancao","year":"2005","unstructured":"Mancao C, Altmann M, Jungnickel B, Hammerschmidt W . Rescue of \u2018crippled\u2019 germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005; 106: 4339\u20134344.","journal-title":"Blood"},{"key":"BFonc2012219_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbrc.2009.09.059","volume":"390","author":"T Sugimoto","year":"2009","unstructured":"Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T et al. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 2009; 390: 48\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2012219_CR33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1365-2141.2008.07193.x","volume":"142","author":"I Daniels","year":"2008","unstructured":"Daniels I, Turzanski J, Haynes AP . A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab. Br J Haematol 2008; 142: 394\u2013403.","journal-title":"Br J Haematol"},{"key":"BFonc2012219_CR34","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.1038\/sj.onc.1210448","volume":"26","author":"E Suzuki","year":"2007","unstructured":"Suzuki E, Umezawa K, Bonavida B . Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007; 26: 6184\u20136193.","journal-title":"Oncogene"},{"key":"BFonc2012219_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/10428190902878471","volume":"50","author":"C Stolz","year":"2009","unstructured":"Stolz C, Schuler M . Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009; 50: 873\u2013885.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2012219_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/jb\/mvq114","volume":"149","author":"Y Hoshino","year":"2011","unstructured":"Hoshino Y, Katsuno Y, Ehata S, Miyazono K . Autocrine TGF-\u03b2 protects breast cancer cells from apoptosis through reduction of BH3-only protein, Bim. J Biochem 2011; 149: 55\u201365.","journal-title":"J Biochem"},{"key":"BFonc2012219_CR37","doi-asserted-by":"publisher","first-page":"9694","DOI":"10.1158\/0008-5472.CAN-07-1522","volume":"67","author":"S Ehata","year":"2007","unstructured":"Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M et al. Transforming growth factor-\u03b2 promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. Cancer Res 2007; 67: 9694\u20139703.","journal-title":"Cancer Res"},{"key":"BFonc2012219_CR38","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/onc.2010.546","volume":"30","author":"S Ehata","year":"2011","unstructured":"Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y et al. Transforming growth factor-\u03b2 decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 2011; 30: 1693\u20131705.","journal-title":"Oncogene"},{"key":"BFonc2012219_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1349-7006.2006.00357.x","volume":"98","author":"S Ehata","year":"2007","unstructured":"Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K et al. Ki26894, a novel transforming growth factor-\u03b2 type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007; 98: 127\u2013133.","journal-title":"Cancer Sci"},{"key":"BFonc2012219_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1128\/MCB.01038-08","volume":"29","author":"D Koinuma","year":"2009","unstructured":"Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M et al. Chromatin immunoprecipitation on microarray analysis of Smad2\/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor-\u03b2 signaling. Mol Cell Biol 2009; 29: 172\u2013186.","journal-title":"Mol Cell Biol"},{"key":"BFonc2012219_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s002620050016","volume":"48","author":"D Shan","year":"2000","unstructured":"Shan D, Ledbetter JA, Press OW . Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673\u2013683.","journal-title":"Cancer Immunol Immunother"},{"key":"BFonc2012219_CR42","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1182\/blood-2003-08-2795","volume":"103","author":"AK Gopal","year":"2004","unstructured":"Gopal AK, Pagel JM, Hedin N, Press OW . Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 2004; 103: 3516\u20133520.","journal-title":"Blood"},{"key":"BFonc2012219_CR43","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1182\/blood-2007-02-076075","volume":"110","author":"D Daniel","year":"2007","unstructured":"Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP et al. Cooperation of the proapoptotic receptor agonist rhApo2L\/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110: 4037\u20134046.","journal-title":"Blood"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2012219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2012219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2012219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:32:11Z","timestamp":1647887531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2012219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,4]]},"references-count":43,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,4,18]]}},"alternative-id":["BFonc2012219"],"URL":"https:\/\/doi.org\/10.1038\/onc.2012.219","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,4]]},"assertion":[{"value":"9 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}